# TCR-T Therapy Sector Canonical URL: https://biopharmsignal.com/sector/tcr-t-therapy TCR-T Therapy includes companies engineering T-cell receptors to recognize specific antigens presented by tumor or diseased cells. It is a specialized cell-therapy category with particular relevance in solid tumors and antigen-defined precision immuno-oncology. Companies currently grouped under TCR-T Therapy: 3 ## Recent Sector News - 2026-10-01 13:00 EST — LEGN — [Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma](https://biopharmsignal.com/news/LEGN/legend-biotech-launches-inaugural-elite-grant-program-to-advance-the-next-genera-328f964f) — Source: Legend Biotech Corporation - 2026-09-25 11:00 EST — LEGN — [Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion](https://biopharmsignal.com/news/LEGN/legend-biotech-presents-carvykti-data-showing-half-of-patients-with-rrmm-remaine-104ae32b) — Source: Legend Biotech Corporation - 2026-09-15 12:00 EST — LEGN — [Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer](https://biopharmsignal.com/news/LEGN/legend-biotech-appoints-ingrid-zhang-as-chief-executive-officer-c5080039) — Source: Legend Biotech Corporation - 2026-09-10 12:00 EST — LEGN — [Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting](https://biopharmsignal.com/news/LEGN/legend-biotech-to-present-updated-long-term-and-real-world-evidence-from-carvykt-2a7786ce) — Source: Legend Biotech Corporation - 2026-09-01 12:00 EST — LEGN — [Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference](https://biopharmsignal.com/news/LEGN/legend-biotech-to-participate-in-the-morgan-stanley-global-healthcare-conference-9365884f) — Source: Legend Biotech Corporation - 2026-08-11 11:00 EST — LEGN — [Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights](https://biopharmsignal.com/news/LEGN/legend-biotech-reports-second-quarter-2026-results-and-recent-highlights-e2e82cac) — Source: Legend Biotech Corporation - 2026-07-28 12:00 EST — LEGN — [Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results](https://biopharmsignal.com/news/LEGN/legend-biotech-to-host-investor-conference-call-on-second-quarter-2026-results-3744bba0) — Source: Legend Biotech Corporation - 2026-07-27 10:00 EST — LEGN — [Legend Biotech Announces CEO Transition](https://biopharmsignal.com/news/LEGN/legend-biotech-announces-ceo-transition-6f26346e) — Source: Legend Biotech Corporation - 2026-06-18 01:21 EST — LEGN — [Legend Biotech Corporation Announces Pricing of Public Offering](https://biopharmsignal.com/news/LEGN/legend-biotech-corporation-announces-pricing-of-public-offering-c0ab1d0b) — Source: Legend Biotech Corporation - 2026-06-17 20:29 EST — LEGN — [Legend Biotech Corporation Announces Proposed Public Offering](https://biopharmsignal.com/news/LEGN/legend-biotech-corporation-announces-proposed-public-offering-3615b70e) — Source: Legend Biotech Corporation - 2026-06-15 12:00 EST — LEGN — [Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma](https://biopharmsignal.com/news/LEGN/legend-biotech-establishes-clinical-proof-of-concept-for-lb2501-a-potential-firs-fb89efa6) — Source: Legend Biotech Corporation - 2026-06-02 13:30 EST — LEGN — [Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)](https://biopharmsignal.com/news/LEGN/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing--075d2e3b) — Source: Legend Biotech Corporation - 2026-06-01 14:00 EST — LEGN — [Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026](https://biopharmsignal.com/news/LEGN/legend-biotech-presents-first-in-human-lb2102-results-in-solid-tumors-and-new-ca-f6f84458) — Source: Legend Biotech Corporation - 2026-05-21 21:00 EST — LEGN — [Legend Biotech Announces Presentations at ASCO 2026](https://biopharmsignal.com/news/LEGN/legend-biotech-announces-presentations-at-asco-2026-b3367a52) — Source: Legend Biotech Corporation - 2026-05-12 11:00 EST — LEGN — [Legend Biotech Reports First Quarter 2026 Results and Recent Highlights](https://biopharmsignal.com/news/LEGN/legend-biotech-reports-first-quarter-2026-results-and-recent-highlights-a43caca4) — Source: Legend Biotech Corporation - 2026-05-04 12:00 EST — LEGN — [Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth](https://biopharmsignal.com/news/LEGN/legend-biotech-expands-scientific-advisory-expertise-to-inform-future-growth-806c85a2) — Source: Legend Biotech Corporation - 2026-04-28 12:00 EST — LEGN — [Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results](https://biopharmsignal.com/news/LEGN/legend-biotech-to-host-investor-conference-call-on-first-quarter-2026-results-5d0924a1) — Source: Legend Biotech Corporation - 2026-03-10 11:00 EST — LEGN — [Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights](https://biopharmsignal.com/news/LEGN/legend-biotech-reports-fourth-quarter-and-full-year-2025-results-and-recent-high-0e5399b6) — Source: Legend Biotech Corporation - 2026-02-24 13:00 EST — LEGN — [Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results](https://biopharmsignal.com/news/LEGN/legend-biotech-to-host-investor-conference-call-on-fourth-quarter-and-full-year--7e132942) — Source: Legend Biotech Corporation - 2026-01-21 13:00 EST — LEGN — [Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use](https://biopharmsignal.com/news/LEGN/legend-biotech-to-present-carvykti-data-at-2026-tandem-meetings-reinforcing-grow-ac1eef31) — Source: Legend Biotech Corporation ## Companies - [ADAP](https://biopharmsignal.com/company/ADAP) — Adaptimmune Therapeutics plc - [LEGN](https://biopharmsignal.com/company/LEGN) — Legend Biotech Corporation - [TCRX](https://biopharmsignal.com/company/TCRX) — TScan Therapeutics, Inc.